Louisiana chucks Risperdal settlement

Share this article:

A Louisiana appeals court has overturned a Risperdal settlement to Johnson & Johnson's advantage. Bloomberg reports that the court tossed a $257.7 million deceptive marketing verdict, saying prosecutors failed to provide enough evidence of wrongdoing.

Despite the local win for J&J, Louisiana is just a minor point in a bigger marketing tangle, which includes allegations from the Department of Justice that the drugmaker's marketing strategies triggered fraudulent government payments for the anti-psychotic, and allegations of tying speaker fees to prescription rates, among others.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions